Tadpole soon to help in the fight against cancer and lymphedema
Lymph circulates in our bodies through a complex network of lymphatic vessels, of which little is known. This network is, however, of major importance for the support of the immune system and the fluid in our body. Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) connected with the Catholic University of Leuven, are the first to indicate that this network can be stu...Lymphedema patients can benefit form exercise
Lymphedema, which is a common problem for breast cancer patients, is an abnormal buildup of fluid that causes swelling, most often in the arms or legs, and develops when lymph vessels or lymph nodes are missing, impaired, damaged, or removed. Secondary lymphedema can develop from infection, malignancy, surgery, scar tissue formation, trauma,// deep vein thrombosis (blood clot in a vein), radiatio...Reason for diabetes drug causing edema discovered
Researchers had been able to find out why the diabetes drug thiazolidinediones (TZDs) can cause //edema. Scientists from the University of Utah had found that the drug TZDs activates a receptor in kidney called peroxisome proliferator-activated receptor gamma (PPAR). This is situated in the collecting duct of the kidney. The activation of the receptor serves to retain the fluid in the...Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema
A new study has revealed that Acute mountain sickness (AMS), which affects about half of those ascending to heights over 3,000m, may lead to life-threatening complications such as pulmonary or cerebral edema. The interest of the general public in AMS is thought to have increased over the past 25 years. This change is partly due to media exposure, trekking guidebooks and the wide ava...DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp.(Nasdaq:DYAX) announced today positive topline results from itsPhase 3, placebo-controlled trial, EDEMA3, for its lead productcandidate DX-88 (ecallantide), for hereditary angioedema (HAE). Awebcast presentation of the EDEMA3 data is scheduled for Tuesday,April 17, 2007 at 12:30 p.m. ET. DX-88, an internally discovered, recombina...Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
Company anticipates second quarter BLA filing for C1-inhibitorreplacement therapy NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. (Lev) today announced positive results fromits pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH)for the acute treatment of hereditary angioedema (HAE). In theacute study, which is part of the company's CHANGE trials(C1-...